Alpha Teknova (NASDAQ:TKNO) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Alpha Teknova (NASDAQ:TKNO) from a hold rating to a buy rating in a research note published on Saturday.

Other research analysts have also recently issued research reports about the company. Weiss Ratings restated a “sell (d-)” rating on shares of Alpha Teknova in a research note on Friday, July 17th. Roth Capital started coverage on Alpha Teknova in a research note on Wednesday, August 5th. They issued a “buy” rating and a $7.00 target price for the company. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Alpha Teknova has a consensus rating of “Hold” and an average target price of $7.00.

Alpha Teknova Stock Performance

Shares of TKNO stock opened at $6.72 on Friday. The company’s fifty day simple moving average is $5.26 and its 200-day simple moving average is $3.78. Alpha Teknova has a 52 week low of $1.91 and a 52 week high of $6.92. The company has a current ratio of 4.49, a quick ratio of 3.48 and a debt-to-equity ratio of 0.21. The company has a market cap of $360.26 million, a PE ratio of -21.68 and a beta of 0.64.

Alpha Teknova (NASDAQ:TKNO) last posted its earnings results on Wednesday, August 5th. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.02. Alpha Teknova had a negative net margin of 38.37% and a negative return on equity of 24.94%. The business had revenue of $12.19 million for the quarter, compared to analyst estimates of $10.95 million. As a group, equities research analysts anticipate that Alpha Teknova will post -0.28 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Roubaix Capital LLC increased its stake in Alpha Teknova by 88.5% during the 1st quarter. Roubaix Capital LLC now owns 1,882,355 shares of the company’s stock worth $5,440,000 after buying an additional 883,823 shares during the period. BlackRock Inc. purchased a new position in Alpha Teknova in the 2nd quarter valued at about $4,997,000. Royce & Associates LP purchased a new position in Alpha Teknova in the 4th quarter valued at about $1,116,000. Balyasny Asset Management L.P. boosted its position in Alpha Teknova by 19.5% in the 2nd quarter. Balyasny Asset Management L.P. now owns 1,000,484 shares of the company’s stock valued at $4,912,000 after buying an additional 163,526 shares during the last quarter. Finally, Massar Capital Management LP grew its stake in shares of Alpha Teknova by 185.7% during the second quarter. Massar Capital Management LP now owns 200,000 shares of the company’s stock valued at $982,000 after acquiring an additional 130,000 shares in the last quarter. 13.81% of the stock is currently owned by hedge funds and other institutional investors.

About Alpha Teknova

Alpha Teknova, Inc (NASDAQ: TKNO) is a life science tools and reagents company that develops, manufactures and distributes proprietary products to support research, drug discovery and biomanufacturing. Its offerings target academic institutions, pharmaceutical and biotechnology firms, and diagnostic developers, with a focus on high-purity reagents and optimized workflows designed to accelerate molecular biology and protein science applications.

The company’s portfolio includes molecular biology reagents, cell culture buffers, in vitro translation kits, custom recombinant proteins, high-throughput screening buffers and other specialized formulations.